Cardioalianza and Novartis present an informational space about Lipoprotein (a)

Cardioalianza and Novartis have introduced a digital information space to raise awareness among the population about lipoprotein(a), a heritable cardiovascular risk factor that experts recommend measuring at least once in a lifetime.

According to data provided by these organizations, it is estimated that one in five people have high levels of lipoprotein(a) (Lp(a)), although most are unaware, since this cardiovascular biomarker is not routinely analyzed. Therefore, coinciding with World Lipoprotein(a) Day, they have launched the first informational portal on Lp(a) to raise awareness of the importance of measuring its levels.

Lp(a) is a blood particle made up of fat and protein, similar to LDL cholesterol (bad cholesterol), but with unique characteristics, as it incorporates apolipoprotein(a). This increases its ability to form plaques in the arteries, potentially being up to six times more atherogenic than LDL, contributing to the development of atherosclerosis.

Cardiovascular diseases are the leading cause of death worldwide, with about 20 million deaths annually, and atherosclerotic cardiovascular disease accounts for approximately 85% of these cases.

Educational Content on Lp(a)

The new digital space on lipoprotein(a) offers practical information through educational content, downloadable materials, and audiovisual pieces featuring health professionals and patients, to explain what Lp(a) is and how it affects cardiovascular risk.

According to Tomás Fajardo, president of Cardioalianza, “lipoprotein(a) is still largely unknown, despite being a key heritable cardiovascular risk factor. With this initiative, we want to promote awareness about the importance of measuring Lp(a) and its implications for cardiovascular health.”

Up to 90% of Lp(a) levels are determined by genetic factors, meaning they can be elevated even in people with healthy lifestyles. The consensus of the Spanish Society of Atherosclerosis (SEA) recommends its measurement in all adults at least once in a lifetime, as it is a persistent risk factor.

Importance of Check-ups

The document emphasizes the need to include lipoprotein(a) measurement in routine health check-ups, through a blood test, to identify individuals at high cardiovascular risk. It is estimated that one in four patients with elevated levels and a history of cardiovascular disease will suffer a cardiovascular event in the next five years.

The president of the SEA, José López Miranda, emphasized that high Lp(a) poses a significantly greater and persistent cardiovascular risk throughout life. Moreover, he highlighted that, in the face of high levels, it is essential to intensify the control of other factors such as LDL cholesterol, high blood pressure, and other modifiable risk factors.

Meanwhile, Esther Espinosa, Director of Communications and Patient Relations at Novartis, pointed out that the company promotes cardiovascular prevention as a key tool to reduce mortality from cardiovascular diseases, bringing to the public information on lipoprotein(a), a little-known risk factor.